数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Philip J. Vickers Director 63 8.53万美元 未持股 2023-05-01
Annalisa Jenkins Director 58 8.83万美元 未持股 2023-05-01
Ian Clark Director 63 7.53万美元 未持股 2023-05-01
Christopher Paige Director 70 8.43万美元 未持股 2023-05-01
Phillip Donenberg Director 62 8.43万美元 未持股 2023-05-01
Gail Farfel Director 59 7.28万美元 未持股 2023-05-01
Gail Farfel Director 59 未披露 未持股 2023-05-01
Philip J. Vickers Director 63 未披露 未持股 2023-05-01
Bruce Booth Chairman of the Board 48 11.03万美元 未持股 2023-05-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Erik Ostrowski President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer 51 135.21万美元 未持股 2023-05-01
Erik Ostrowski President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer 50 未披露 未持股 2023-05-01
Steven Avruch Chief Legal Officer and Secretary 63 未披露 未持股 2023-05-01
Azadeh Golipour Chief Technology Officer 44 102.60万美元 未持股 2023-05-01
Deanna Petersen Chief Business Officer 61 未披露 未持股 2023-05-01
Essra Ridha Chief Medical Officer 40 未披露 未持股 2023-05-01

董事简历

中英对照 |  中文 |  英文
Philip J. Vickers

Philip J. Vickers,他曾一直担任Revance Therapeutics, Inc.的董事(2015年2月以来)。他拥有超过25年的制药行业经验。2011年以来,他一直担任Shire公司的全球研发主管,在那里他负责临床前研发、临床研究、法规事务、医疗事务。他负责组织日益增长的产品组合,并在Shire公司全球商业策略的开发和执行中起着至关重要的作用。他是Shire公司的执行和管道委员会的成员。任职Shire公司之前,他曾担任Resolvyx Pharmaceuticals公司(Resolvyx公司,生物制药公司)的首席科学官兼总裁(从2009年到2011年),在那里他曾担任董事会成员,负责所有临床前和临床研究、与投资者和外部业务发展合伙人的合伙关系,以及建立外部协作。任职Resolvyx公司之前,他曾担任国际生物制药公司(包括Boehringer-Ingelheim Pharmaceuticals公司、Pfizer公司、Merck Frosst Centre)的多种职务。他持有the University of Toronto的生物化学博士学位、the University of Salford, Manchester的应用生物化学科学学士学位。他也曾是the National Cancer Institute(位于马里兰州的贝塞斯达)的客座研究员。


Philip J. Vickers,has served as a member of Avrobio, Inc. board of directors since January 2019. Dr. Vickers was the chief executive officer of Faze Medicines, a biotechnology company from January 2021 to November 2022. From November 2017 until December 2020, Dr. Vickers served as the president and chief executive officer and a member of the board of directors of Northern Biologics Inc., a biotechnology company. From June 2013 until June 2017, Dr. Vickers served as global head of research and development and a member of the executive committee of Shire plc, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. From October 2010 to September 2013, Dr. Vickers served as the senior vice president, head of research and development, human genetic therapies at Shire. Prior to Shire, Dr. Vickers held positions of increasing responsibility in research and development at Merck & Co., Inc., Pfizer Inc., Boehringer-Ingelheim International GmbH and Resolvyx Pharmaceuticals, Inc. Dr. Vickers serves on the board of directors of Revance Therapeutics, Inc., or Revance (Nasdaq: RVNC), a biotechnology company, and will continue to serve on the Revance board until the Revance 2023 annual meeting. Dr. Vickers also serves as a scientific advisor to the PTEN Research Foundation. Dr. Vickers obtained his Ph.D. in biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
Philip J. Vickers,他曾一直担任Revance Therapeutics, Inc.的董事(2015年2月以来)。他拥有超过25年的制药行业经验。2011年以来,他一直担任Shire公司的全球研发主管,在那里他负责临床前研发、临床研究、法规事务、医疗事务。他负责组织日益增长的产品组合,并在Shire公司全球商业策略的开发和执行中起着至关重要的作用。他是Shire公司的执行和管道委员会的成员。任职Shire公司之前,他曾担任Resolvyx Pharmaceuticals公司(Resolvyx公司,生物制药公司)的首席科学官兼总裁(从2009年到2011年),在那里他曾担任董事会成员,负责所有临床前和临床研究、与投资者和外部业务发展合伙人的合伙关系,以及建立外部协作。任职Resolvyx公司之前,他曾担任国际生物制药公司(包括Boehringer-Ingelheim Pharmaceuticals公司、Pfizer公司、Merck Frosst Centre)的多种职务。他持有the University of Toronto的生物化学博士学位、the University of Salford, Manchester的应用生物化学科学学士学位。他也曾是the National Cancer Institute(位于马里兰州的贝塞斯达)的客座研究员。
Philip J. Vickers,has served as a member of Avrobio, Inc. board of directors since January 2019. Dr. Vickers was the chief executive officer of Faze Medicines, a biotechnology company from January 2021 to November 2022. From November 2017 until December 2020, Dr. Vickers served as the president and chief executive officer and a member of the board of directors of Northern Biologics Inc., a biotechnology company. From June 2013 until June 2017, Dr. Vickers served as global head of research and development and a member of the executive committee of Shire plc, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. From October 2010 to September 2013, Dr. Vickers served as the senior vice president, head of research and development, human genetic therapies at Shire. Prior to Shire, Dr. Vickers held positions of increasing responsibility in research and development at Merck & Co., Inc., Pfizer Inc., Boehringer-Ingelheim International GmbH and Resolvyx Pharmaceuticals, Inc. Dr. Vickers serves on the board of directors of Revance Therapeutics, Inc., or Revance (Nasdaq: RVNC), a biotechnology company, and will continue to serve on the Revance board until the Revance 2023 annual meeting. Dr. Vickers also serves as a scientific advisor to the PTEN Research Foundation. Dr. Vickers obtained his Ph.D. in biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
Annalisa Jenkins

Annalisa Jenkins,她一直担任Avrobio, Inc.董事会的成员(2015年2月以来)。她目前担任Dimension Therapeutics公司(一家制药公司,她于2014年9月加入Dimension Therapeutics)的首席执行官。从2013年10月到2014年3月,她曾担任Merck Serono Pharmaceuticals公司(Merck Serono、制药公司)的执行副总裁、全球研发主管。此前,她曾担任Merck Serono公司的执行副总裁,负责全球开发和医疗,也曾担任Merck Serono公司的执行委员会成员(从2011年9月到2013年10月)。此前,她曾担任Bristol-Myers Squibb Company(医药公司)的多种领导职务,最近担任高级副总裁,以及全球医疗事务主管(从2009年到2011年)。职业生涯早期,她曾担任海湾冲突中英国皇家海军的医疗官,并成为海军少校军衔的外科医生。她目前任职于Ardelyx公司(NASDAQ:ARDX)的董事会(2015年4月以来)。她也任职于Biothera Pharmaceuticals公司、iOX Therapeutics Limited 公司、MedCity公司的董事会。她是FDA的科学委员会(建议FDA领导,涉及复杂的科学和技术事务)成员,以及the European Commission's Scientific Panel for Health(一个科学专家组,负责帮助实现更好的健康和福祉)的成员。她也任职于Women in Bio、the Center for Talent Innovation(位于英国)的董事会,并任职于the Advisory Panel of the Healthcare Businesswomen's Association。她持有St. Bartholomew's Hospital in the University of London的医药学位,并接受UK National Health Service的心血管医学训练。


Annalisa Jenkins,has served as a member of Avrobio, Inc. board of directors since March 2018. From November 2017 until April 2019, Dr. Jenkins served as the chief executive officer of PlaqueTec Ltd., a biotechnology company focusing on coronary artery disease treatment and prevention. Previously, Dr. Jenkins served as the president and chief executive officer and a member of the board of directors of Dimension Therapeutics, Inc., a biotechnology company focused on rare and metabolic diseases associated with the liver, from September 2014 until its sale to Ultragenyx Pharmaceutical Inc. in November 2017. From October 2013 to March 2014, Dr. Jenkins served as executive vice president, head of global research and development for Merck Serono Pharmaceuticals, a biopharmaceutical company. Previously, from September 2011 to October 2013, she served as Merck Serono's executive vice president, global development and medical, and was a member of Merck Serono's executive committee. Prior to that, Dr. Jenkins pursued a 15-year career at Bristol-Myers Squibb Company, a biopharmaceutical company, where, from July 2009 to June 2011, she was a senior vice president and head of global medical affairs. Dr. Jenkins currently serves on the board of Genomics England, a UK government entity dedicated to advancing the 100,000 Genomes Project. Dr. Jenkins also serves on the board of directors of Oncimmune Holdings plc (LSE: ONC), Affimed N.V. (Nasdaq: AFMD), Compass Pathways (Nasdaq: CMPS), Mereo Biopharma Group plc (Nasdaq: MREO), and a number of privately held biotechnology and life science companies, and serves as a trustee to a number of non-profit organizations. Dr. Jenkins previously served on the board of numerous biotechnology and life science companies, including AgeX Therapeutics, Inc. (NYSE American: AGE), Silence Therapeutics, Ardelyx, Inc., OncoSec Medical Incorporated, and Sensyne Health plc., and she served as a committee member of the science board to the FDA, which advised leadership on complex scientific and technical issues. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew's Hospital in the University of London and subsequently trained in cardiovascular medicine in the UK National Health Service. Earlier in her career, Dr. Jenkins served as a medical officer in the British Royal Navy.
Annalisa Jenkins,她一直担任Avrobio, Inc.董事会的成员(2015年2月以来)。她目前担任Dimension Therapeutics公司(一家制药公司,她于2014年9月加入Dimension Therapeutics)的首席执行官。从2013年10月到2014年3月,她曾担任Merck Serono Pharmaceuticals公司(Merck Serono、制药公司)的执行副总裁、全球研发主管。此前,她曾担任Merck Serono公司的执行副总裁,负责全球开发和医疗,也曾担任Merck Serono公司的执行委员会成员(从2011年9月到2013年10月)。此前,她曾担任Bristol-Myers Squibb Company(医药公司)的多种领导职务,最近担任高级副总裁,以及全球医疗事务主管(从2009年到2011年)。职业生涯早期,她曾担任海湾冲突中英国皇家海军的医疗官,并成为海军少校军衔的外科医生。她目前任职于Ardelyx公司(NASDAQ:ARDX)的董事会(2015年4月以来)。她也任职于Biothera Pharmaceuticals公司、iOX Therapeutics Limited 公司、MedCity公司的董事会。她是FDA的科学委员会(建议FDA领导,涉及复杂的科学和技术事务)成员,以及the European Commission's Scientific Panel for Health(一个科学专家组,负责帮助实现更好的健康和福祉)的成员。她也任职于Women in Bio、the Center for Talent Innovation(位于英国)的董事会,并任职于the Advisory Panel of the Healthcare Businesswomen's Association。她持有St. Bartholomew's Hospital in the University of London的医药学位,并接受UK National Health Service的心血管医学训练。
Annalisa Jenkins,has served as a member of Avrobio, Inc. board of directors since March 2018. From November 2017 until April 2019, Dr. Jenkins served as the chief executive officer of PlaqueTec Ltd., a biotechnology company focusing on coronary artery disease treatment and prevention. Previously, Dr. Jenkins served as the president and chief executive officer and a member of the board of directors of Dimension Therapeutics, Inc., a biotechnology company focused on rare and metabolic diseases associated with the liver, from September 2014 until its sale to Ultragenyx Pharmaceutical Inc. in November 2017. From October 2013 to March 2014, Dr. Jenkins served as executive vice president, head of global research and development for Merck Serono Pharmaceuticals, a biopharmaceutical company. Previously, from September 2011 to October 2013, she served as Merck Serono's executive vice president, global development and medical, and was a member of Merck Serono's executive committee. Prior to that, Dr. Jenkins pursued a 15-year career at Bristol-Myers Squibb Company, a biopharmaceutical company, where, from July 2009 to June 2011, she was a senior vice president and head of global medical affairs. Dr. Jenkins currently serves on the board of Genomics England, a UK government entity dedicated to advancing the 100,000 Genomes Project. Dr. Jenkins also serves on the board of directors of Oncimmune Holdings plc (LSE: ONC), Affimed N.V. (Nasdaq: AFMD), Compass Pathways (Nasdaq: CMPS), Mereo Biopharma Group plc (Nasdaq: MREO), and a number of privately held biotechnology and life science companies, and serves as a trustee to a number of non-profit organizations. Dr. Jenkins previously served on the board of numerous biotechnology and life science companies, including AgeX Therapeutics, Inc. (NYSE American: AGE), Silence Therapeutics, Ardelyx, Inc., OncoSec Medical Incorporated, and Sensyne Health plc., and she served as a committee member of the science board to the FDA, which advised leadership on complex scientific and technical issues. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew's Hospital in the University of London and subsequently trained in cardiovascular medicine in the UK National Health Service. Earlier in her career, Dr. Jenkins served as a medical officer in the British Royal Navy.
Ian Clark

Ian Clark自2020年8月以来一直担任我们的董事会成员。2017年9月至2020年9月,Clark先生曾担任Blackstone Life Sciences(前身为Clarus Ventures,LLC,一家风险投资公司)的运营合伙人。克拉克先生自2019年1月起担任Takeda Pharmaceutical Company Limited上市生物制药公司董事会成员,自2018年1月起担任AVROBIO,Inc.董事,自2017年1月起担任CorvusPharmaceuticals,Inc.董事,自2017年1月起担任GuardantHealth,Inc.董事,自2016年12月起担任Agios制药公司董事。克拉克先生分别于2018年5月至2020年4月和2017年2月至2019年1月担任上市生物制药公司Forty Seven Inc.和Shire Pharmaceuticals,Inc.的董事会成员。他还曾于2017年1月至2017年10月担任KitePharma,Inc.(当时是一家上市生物制药公司)的董事会成员。他曾于2010年1月至2016年12月担任Genentech,Inc.首席执行官。在此之前,他从2009年4月到2009年12月担任罗氏集团执行Vice President和首席营销官。在加入罗氏集团之前,Clark先生从2003年1月到2009年3月在Genentech担任过多个高级管理职位,包括全球产品战略主管、首席营销官、高级副总裁,生物肿瘤学总经理和商业运营执行Vice President。在Genentech之前,Clark先生在生物制药行业工作了23年,在英国,法国和东欧的Novartis International AG,IVAX Pharmaceuticals,Inc.和Sanofi S.A.担任高级职位。他的职业生涯始于孟山都公司(Monsanto Corporation)的子公司G.D.Searle,LLC,在销售与市场营销任职。Clark先生在南汉普顿大学(Southhampton University)获得生物学学士学位。


Ian Clark,has served as Chairperson of Kyverna Therapeutics, Inc. board of directors and as a member of Kyverna Therapeutics, Inc. board of directors since September 2021. Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as Chief Executive Officer and member of the board of directors for Genentech, Inc., until his retirement in December 2016. During his seven-year tenure as Chief Executive Officer of Genentech, Mr. Clark and his team brought eleven new medicines to market for patients with rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Prior to that, Mr. Clark served as the Executive Vice President and Chief Marketing Officer of the Roche Group from April 2009 to December 2009. Prior to his time at the Roche Group, Mr. Clark held several senior management positions at Genentech Inc. from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. Prior to joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry holding several positions of increasing responsibility at Novartis AG (NYSE: NVS, SIX: NOVN), Sanofi (Nasdaq: SNY), Ivax and Searle, working in the USA, United Kingdom, Canada, Eastern Europe and France. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies: Takeda Pharmaceutical Company Limited (NYSE: TAK), Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), Guardant Health, Inc. (Nasdaq: GH), Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) and Avrobio, Inc. (Nasdaq: AVRO). Mr. Clark previously served on the boards of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), Forty Seven Inc., Shire Pharmaceuticals, Inc., Kite Pharma, Inc., TerraVia Holdings, Inc., Gyroscope Therapeutics Limited, Dendreon Pharmaceuticals LLC and Vernalis (R&D) Limited. He was also on the Board of Biotechnology Industry Association, on the BioFulcrum Board of the Gladstone Institute and on the Economic Advisory Council of the 12th District of the Federal Reserve. In addition, he served as an advisor to Blackstone Life Sciences, formerly Clarus Ventures, LLC, a venture capital firm, from September 2017 to September 2020, as well as to Perella Weinberg Partners LP and Lazard Ltd. Mr. Clark received his Bachelor of Science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.
Ian Clark自2020年8月以来一直担任我们的董事会成员。2017年9月至2020年9月,Clark先生曾担任Blackstone Life Sciences(前身为Clarus Ventures,LLC,一家风险投资公司)的运营合伙人。克拉克先生自2019年1月起担任Takeda Pharmaceutical Company Limited上市生物制药公司董事会成员,自2018年1月起担任AVROBIO,Inc.董事,自2017年1月起担任CorvusPharmaceuticals,Inc.董事,自2017年1月起担任GuardantHealth,Inc.董事,自2016年12月起担任Agios制药公司董事。克拉克先生分别于2018年5月至2020年4月和2017年2月至2019年1月担任上市生物制药公司Forty Seven Inc.和Shire Pharmaceuticals,Inc.的董事会成员。他还曾于2017年1月至2017年10月担任KitePharma,Inc.(当时是一家上市生物制药公司)的董事会成员。他曾于2010年1月至2016年12月担任Genentech,Inc.首席执行官。在此之前,他从2009年4月到2009年12月担任罗氏集团执行Vice President和首席营销官。在加入罗氏集团之前,Clark先生从2003年1月到2009年3月在Genentech担任过多个高级管理职位,包括全球产品战略主管、首席营销官、高级副总裁,生物肿瘤学总经理和商业运营执行Vice President。在Genentech之前,Clark先生在生物制药行业工作了23年,在英国,法国和东欧的Novartis International AG,IVAX Pharmaceuticals,Inc.和Sanofi S.A.担任高级职位。他的职业生涯始于孟山都公司(Monsanto Corporation)的子公司G.D.Searle,LLC,在销售与市场营销任职。Clark先生在南汉普顿大学(Southhampton University)获得生物学学士学位。
Ian Clark,has served as Chairperson of Kyverna Therapeutics, Inc. board of directors and as a member of Kyverna Therapeutics, Inc. board of directors since September 2021. Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as Chief Executive Officer and member of the board of directors for Genentech, Inc., until his retirement in December 2016. During his seven-year tenure as Chief Executive Officer of Genentech, Mr. Clark and his team brought eleven new medicines to market for patients with rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Prior to that, Mr. Clark served as the Executive Vice President and Chief Marketing Officer of the Roche Group from April 2009 to December 2009. Prior to his time at the Roche Group, Mr. Clark held several senior management positions at Genentech Inc. from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. Prior to joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry holding several positions of increasing responsibility at Novartis AG (NYSE: NVS, SIX: NOVN), Sanofi (Nasdaq: SNY), Ivax and Searle, working in the USA, United Kingdom, Canada, Eastern Europe and France. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies: Takeda Pharmaceutical Company Limited (NYSE: TAK), Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), Guardant Health, Inc. (Nasdaq: GH), Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) and Avrobio, Inc. (Nasdaq: AVRO). Mr. Clark previously served on the boards of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), Forty Seven Inc., Shire Pharmaceuticals, Inc., Kite Pharma, Inc., TerraVia Holdings, Inc., Gyroscope Therapeutics Limited, Dendreon Pharmaceuticals LLC and Vernalis (R&D) Limited. He was also on the Board of Biotechnology Industry Association, on the BioFulcrum Board of the Gladstone Institute and on the Economic Advisory Council of the 12th District of the Federal Reserve. In addition, he served as an advisor to Blackstone Life Sciences, formerly Clarus Ventures, LLC, a venture capital firm, from September 2017 to September 2020, as well as to Perella Weinberg Partners LP and Lazard Ltd. Mr. Clark received his Bachelor of Science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.
Christopher Paige

Christopher Paige自2016年1月以来一直担任我们的董事会成员。Paige博士是多伦多大学(University of Toronto)医学生物物理学和免疫学部门的教授。1997年,他担任大学健康网络的研究Vice President,现在担任高级科学家。Paige博士于1990年成为关节炎和自身免疫研究中心的创始主任以及韦尔斯利医院的研究主任。他于1980年成为瑞士巴塞尔免疫学研究所(the Basel Institute for Immunology)的成员,直到1987年加入安大略省癌症研究所(the Ontario Cancer Institute)担任高级科学家。Paige博士于1974年在圣母大学(University of Notre Dame)获得生物学学士学位,并于1979年在康奈尔大学医学科学研究生院(Cornell University Graduate School of Medical Sciences)斯隆-凯特林部获得免疫学博士学位。


Christopher Paige,has served as a member of Avrobio, Inc. board of directors since January 2016. Dr. Paige is a professor in the departments of medical biophysics and immunology at the University of Toronto and has served in that role since 1987. He also holds the position of Emeritus Senior Scientist at University Health Network (UHN) after having served as a senior scientist at UHN from 1987 to 2021. From 1997 to October 2016, he served as the vice president, research of UHN. In 1990, Dr. Paige became the founding director of the Arthritis and Autoimmunity Research Centre as well as director of research at The Wellesley Hospital. He became a member of the Basel Institute for Immunology in Switzerland in 1980 where he worked until joining the Ontario Cancer Institute as a senior scientist in 1987. Dr. Paige also has experience serving on the board of directors of privately held companies. Dr. Paige earned a B.S. in biology at the University of Notre Dame in 1974 and a Ph.D. in immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979.
Christopher Paige自2016年1月以来一直担任我们的董事会成员。Paige博士是多伦多大学(University of Toronto)医学生物物理学和免疫学部门的教授。1997年,他担任大学健康网络的研究Vice President,现在担任高级科学家。Paige博士于1990年成为关节炎和自身免疫研究中心的创始主任以及韦尔斯利医院的研究主任。他于1980年成为瑞士巴塞尔免疫学研究所(the Basel Institute for Immunology)的成员,直到1987年加入安大略省癌症研究所(the Ontario Cancer Institute)担任高级科学家。Paige博士于1974年在圣母大学(University of Notre Dame)获得生物学学士学位,并于1979年在康奈尔大学医学科学研究生院(Cornell University Graduate School of Medical Sciences)斯隆-凯特林部获得免疫学博士学位。
Christopher Paige,has served as a member of Avrobio, Inc. board of directors since January 2016. Dr. Paige is a professor in the departments of medical biophysics and immunology at the University of Toronto and has served in that role since 1987. He also holds the position of Emeritus Senior Scientist at University Health Network (UHN) after having served as a senior scientist at UHN from 1987 to 2021. From 1997 to October 2016, he served as the vice president, research of UHN. In 1990, Dr. Paige became the founding director of the Arthritis and Autoimmunity Research Centre as well as director of research at The Wellesley Hospital. He became a member of the Basel Institute for Immunology in Switzerland in 1980 where he worked until joining the Ontario Cancer Institute as a senior scientist in 1987. Dr. Paige also has experience serving on the board of directors of privately held companies. Dr. Paige earned a B.S. in biology at the University of Notre Dame in 1974 and a Ph.D. in immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979.
Phillip Donenberg

Phillip Donenberg是我们的董事会成员,在本招股说明书所包含的注册声明生效后立即生效。自2018年7月16日起,多嫩伯格先生已被任命为Depomed,Inc.的首席财务官兼高级副总裁。在此之前,多嫩伯格先生将继续担任Avexis,Inc.的高级副总裁兼首席财务官,此前他曾于2016年9月至2017年10月担任该公司的Vice President兼公司财务总监。他曾担任RestorGenex Corporation的首席财务官(2014年5月至2016年1月)、Diffusion Pharmaceuticals LLC的首席财务官(2013年9月至2014年5月),以及7Wire Ventures LLC的首席财务官(2016年9月至2014年5月)。在此之前,从1998年7月到2013年6月Biosante Pharmaceuticals,Inc.与ANIP Pharmaceuticals,Inc.合并,Donenberg先生担任Biosante Pharmaceuticals,Inc.的首席财务官。Donenberg先生还拥有在私人控股公司董事会任职的经验。Donenberg先生拥有伊利诺伊大学香槟-厄巴纳商学院(University of Illinois Champaign-Urbana College of Business)的会计学学士学位,并且是一名注册会计师。


Phillip Donenberg,has served as a member of Avrobio, Inc. board of directors and audit committee chair since June 2018. Mr. Donenberg served as senior vice president and chief financial officer of Jaguar Gene Therapy, LLC, a privately held early-stage gene therapy company from February 2020 to March 2023. From July 2018 to November 2018, Mr. Donenberg served as the chief financial officer and senior vice president of Assertio Therapeutics, Inc. (Nasdaq: ASRT), a pharmaceutical company. Previously, Mr. Donenberg served at AveXis, Inc. (now a Novartis company), a gene therapy company, as senior vice president and chief financial officer from October 2017 to June 2018 and as vice president, corporate controller from September 2016 to October 2017. He was the chief financial officer of RestorGenex Corporation from May 2014 to January 2016, when RestorGenex merged with Diffusion Pharmaceuticals LLC, a pharmaceutical company, and served as the merged company's consultant chief financial officer until September 2016, and the chief financial officer of 7wire Ventures LLC, an early-stage healthcare venture fund, from September 2013 to May 2014. Prior to that time, Mr. Donenberg served as the chief financial officer of BioSante Pharmaceuticals, Inc. from July 1998 to June 2013, when BioSante merged with ANIP Pharmaceuticals, Inc. Mr. Donenberg currently serves on the board of directors and as audit committee chair of Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a gene therapy company, and also has experience serving on the boards of directors of privately held companies. Mr. Donenberg holds a B.S. in accountancy from the University of Illinois Champaign-Urbana College of Business and is a Certified Public Accountant.
Phillip Donenberg是我们的董事会成员,在本招股说明书所包含的注册声明生效后立即生效。自2018年7月16日起,多嫩伯格先生已被任命为Depomed,Inc.的首席财务官兼高级副总裁。在此之前,多嫩伯格先生将继续担任Avexis,Inc.的高级副总裁兼首席财务官,此前他曾于2016年9月至2017年10月担任该公司的Vice President兼公司财务总监。他曾担任RestorGenex Corporation的首席财务官(2014年5月至2016年1月)、Diffusion Pharmaceuticals LLC的首席财务官(2013年9月至2014年5月),以及7Wire Ventures LLC的首席财务官(2016年9月至2014年5月)。在此之前,从1998年7月到2013年6月Biosante Pharmaceuticals,Inc.与ANIP Pharmaceuticals,Inc.合并,Donenberg先生担任Biosante Pharmaceuticals,Inc.的首席财务官。Donenberg先生还拥有在私人控股公司董事会任职的经验。Donenberg先生拥有伊利诺伊大学香槟-厄巴纳商学院(University of Illinois Champaign-Urbana College of Business)的会计学学士学位,并且是一名注册会计师。
Phillip Donenberg,has served as a member of Avrobio, Inc. board of directors and audit committee chair since June 2018. Mr. Donenberg served as senior vice president and chief financial officer of Jaguar Gene Therapy, LLC, a privately held early-stage gene therapy company from February 2020 to March 2023. From July 2018 to November 2018, Mr. Donenberg served as the chief financial officer and senior vice president of Assertio Therapeutics, Inc. (Nasdaq: ASRT), a pharmaceutical company. Previously, Mr. Donenberg served at AveXis, Inc. (now a Novartis company), a gene therapy company, as senior vice president and chief financial officer from October 2017 to June 2018 and as vice president, corporate controller from September 2016 to October 2017. He was the chief financial officer of RestorGenex Corporation from May 2014 to January 2016, when RestorGenex merged with Diffusion Pharmaceuticals LLC, a pharmaceutical company, and served as the merged company's consultant chief financial officer until September 2016, and the chief financial officer of 7wire Ventures LLC, an early-stage healthcare venture fund, from September 2013 to May 2014. Prior to that time, Mr. Donenberg served as the chief financial officer of BioSante Pharmaceuticals, Inc. from July 1998 to June 2013, when BioSante merged with ANIP Pharmaceuticals, Inc. Mr. Donenberg currently serves on the board of directors and as audit committee chair of Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a gene therapy company, and also has experience serving on the boards of directors of privately held companies. Mr. Donenberg holds a B.S. in accountancy from the University of Illinois Champaign-Urbana College of Business and is a Certified Public Accountant.
Gail Farfel

Gail Farfel,Farfel博士自2022年9月起担任公司首席执行官。Farfel博士自2015年6月起在Zogenix, Inc.(“Zogenix”)担任首席开发官,该公司是一家致力于开发罕见病疗法并将其商业化的全球性生物制药公司。Farfel博士为公司带来了超过25年的罕见病药物开发和监管经验。在Zogenix,她担任执行副总裁兼全球首席开发官,领导所有产品开发活动,包括临床前和临床开发以及监管策略。在加入Zogenix之前,Farfel博士是Marinus Phamaceuticals Inc.(纳斯达克股票代码:MRNS)的首席临床和监管官,在那里她制定并监督针对成人和儿童癫痫疾病的临床、医疗和监管策略,包括一种儿童癫痫孤儿疾病。在此之前,她是诺华制药公司(纽约证券交易所代码:NVS)的副总裁兼神经科学临床开发和医疗事务治疗领域负责人,负责精神病学、多发性硬化症、阿尔茨海默症和帕金森病的产品组合。Farfel博士在神经精神药理学和药物效应领域撰写了50多篇科学文章和演讲,目前担任DURECT公司(纳斯达克股票代码:DRRX)和Avrobio公司(纳斯达克股票代码:AVRO)的董事会成员。Farfel博士也是美国实验神经治疗学会的理事。Farfel博士拥有芝加哥大学神经精神药理学博士学位,并获得了金斯伯格博士论文优秀奖,并且是医学和生物科学校友委员会的董事。Farfel博士还拥有弗吉尼亚大学生物化学学士学位。


Gail Farfel,Gail Farfel has served as Chief Executive Officer of the Company since September 2022. Dr. Farfel joined the Company after serving as Chief Development Officer at Zogenix, Inc., a global biopharmaceutical company committed to developing and commercializing therapies for rare diseases, since June 2015. At Zogenix, she served as an executive vice president and global chief development officer where she led all product development activities, including preclinical and clinical development and regulatory strategy. Prior to joining Zogenix, Dr. Farfel was chief clinical and regulatory officer at Marinus Phamaceuticals Inc. (NASDAQ: MRNS), where she established and oversaw clinical, medical, and regulatory strategies for adult and pediatric seizure disorders, including a pediatric epileptic orphan disease. Prior to that, she was vice president, therapeutic area head for neuroscience clinical development and medical affairs at Novartis Pharmaceuticals Corporation (NYSE: NVS), where she oversaw a portfolio of products in psychiatry, multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Dr. Farfel has authored more than 50 scientific articles and presentations in the areas of neuropsychopharmacology and drug effects and currently serves on the boards of directors of DURECT Corporation (NASDAQ: DRRX) and Avrobio Inc. (NASDAQ: AVRO). Dr. Farfel is also a director on the Board of the American Society for Experimental Neurotherapeutics. Dr. Farfel holds a Ph.D. in neuropsychopharmacology from the University of Chicago, where she is a director on the Medical and Biological Sciences Alumni Board. Dr. Farfel also holds a Bachelor of Arts degree in biochemistry from the University of Virginia.
Gail Farfel,Farfel博士自2022年9月起担任公司首席执行官。Farfel博士自2015年6月起在Zogenix, Inc.(“Zogenix”)担任首席开发官,该公司是一家致力于开发罕见病疗法并将其商业化的全球性生物制药公司。Farfel博士为公司带来了超过25年的罕见病药物开发和监管经验。在Zogenix,她担任执行副总裁兼全球首席开发官,领导所有产品开发活动,包括临床前和临床开发以及监管策略。在加入Zogenix之前,Farfel博士是Marinus Phamaceuticals Inc.(纳斯达克股票代码:MRNS)的首席临床和监管官,在那里她制定并监督针对成人和儿童癫痫疾病的临床、医疗和监管策略,包括一种儿童癫痫孤儿疾病。在此之前,她是诺华制药公司(纽约证券交易所代码:NVS)的副总裁兼神经科学临床开发和医疗事务治疗领域负责人,负责精神病学、多发性硬化症、阿尔茨海默症和帕金森病的产品组合。Farfel博士在神经精神药理学和药物效应领域撰写了50多篇科学文章和演讲,目前担任DURECT公司(纳斯达克股票代码:DRRX)和Avrobio公司(纳斯达克股票代码:AVRO)的董事会成员。Farfel博士也是美国实验神经治疗学会的理事。Farfel博士拥有芝加哥大学神经精神药理学博士学位,并获得了金斯伯格博士论文优秀奖,并且是医学和生物科学校友委员会的董事。Farfel博士还拥有弗吉尼亚大学生物化学学士学位。
Gail Farfel,Gail Farfel has served as Chief Executive Officer of the Company since September 2022. Dr. Farfel joined the Company after serving as Chief Development Officer at Zogenix, Inc., a global biopharmaceutical company committed to developing and commercializing therapies for rare diseases, since June 2015. At Zogenix, she served as an executive vice president and global chief development officer where she led all product development activities, including preclinical and clinical development and regulatory strategy. Prior to joining Zogenix, Dr. Farfel was chief clinical and regulatory officer at Marinus Phamaceuticals Inc. (NASDAQ: MRNS), where she established and oversaw clinical, medical, and regulatory strategies for adult and pediatric seizure disorders, including a pediatric epileptic orphan disease. Prior to that, she was vice president, therapeutic area head for neuroscience clinical development and medical affairs at Novartis Pharmaceuticals Corporation (NYSE: NVS), where she oversaw a portfolio of products in psychiatry, multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Dr. Farfel has authored more than 50 scientific articles and presentations in the areas of neuropsychopharmacology and drug effects and currently serves on the boards of directors of DURECT Corporation (NASDAQ: DRRX) and Avrobio Inc. (NASDAQ: AVRO). Dr. Farfel is also a director on the Board of the American Society for Experimental Neurotherapeutics. Dr. Farfel holds a Ph.D. in neuropsychopharmacology from the University of Chicago, where she is a director on the Medical and Biological Sciences Alumni Board. Dr. Farfel also holds a Bachelor of Arts degree in biochemistry from the University of Virginia.
Gail Farfel

Gail Farfel,自2020年10月起担任Avrobio,Inc.董事会成员。Farfel博士是生物制药公司ProMIS Neurosciences公司的首席执行官,自2022年9月起担任该职务。2015年6月至2022年9月,Farfel博士担任生物制药公司Zogenix公司执行副总裁兼首席开发官。在此之前,Farfel博士是Marinus制药(纳斯达克:MRNS)的首席临床和监管官,负责制定和监督成人和儿童癫痫发作疾病的临床、医疗和监管策略,其中包括一种儿童癫痫孤儿病。她还曾在诺华制药公司担任副总裁、神经科学临床开发和医疗事务的治疗领域负责人,负责监督多发性硬化症、阿尔茨海默病和帕金森病的产品组合。Farfel博士在Durect Corporation(纳斯达克:DRRX)的董事会任职。她此前曾在Zogenix, Inc.(ZGNX)的全资子公司Zogenix International Ltd.的董事会任职。Farfel博士拥有芝加哥大学神经精神药理学博士学位,在那里她获得了金斯堡论文优秀奖,并且是医学和生物科学校友委员会的董事。她还拥有弗吉尼亚大学生物化学学士学位。


Gail Farfel,has served as a member of Avrobio, Inc. board of directors since October 2020. Dr. Farfel is the chief executive officer of ProMIS Neurosciences, Inc., a biopharmaceutical company, and has served in this role since September 2022. From June 2015 to September 2022, Dr. Farfel was executive vice president and chief development officer of Zogenix Inc., a biopharmaceutical company. Previously, Dr. Farfel was chief clinical and regulatory officer of Marinus Pharmaceuticals (Nasdaq: MRNS), establishing and overseeing clinical, medical and regulatory strategies for adult and pediatric seizure disorders, including a pediatric epileptic orphan disease. She also previously served as vice president, therapeutic area head for neuroscience clinical development and medical affairs at Novartis Pharmaceuticals Corporation, where she oversaw a portfolio of products for multiple sclerosis, Alzheimer's disease and Parkinson's disease. Dr. Farfel serves on the board of directors of Durect Corporation (Nasdaq: DRRX). She previously served on the board of directors of Zogenix International Ltd., a wholly owned subsidiary of Zogenix, Inc. (Nasdaq: ZGNX). Dr Farfel holds a Ph.D. in neuropsychopharmacology from the University of Chicago, where she received the Ginsburg Prize for Dissertation Excellence and is a director on the Medical and Biological Sciences Alumni Board. She also holds a B.S in biochemistry from the University of Virginia.
Gail Farfel,自2020年10月起担任Avrobio,Inc.董事会成员。Farfel博士是生物制药公司ProMIS Neurosciences公司的首席执行官,自2022年9月起担任该职务。2015年6月至2022年9月,Farfel博士担任生物制药公司Zogenix公司执行副总裁兼首席开发官。在此之前,Farfel博士是Marinus制药(纳斯达克:MRNS)的首席临床和监管官,负责制定和监督成人和儿童癫痫发作疾病的临床、医疗和监管策略,其中包括一种儿童癫痫孤儿病。她还曾在诺华制药公司担任副总裁、神经科学临床开发和医疗事务的治疗领域负责人,负责监督多发性硬化症、阿尔茨海默病和帕金森病的产品组合。Farfel博士在Durect Corporation(纳斯达克:DRRX)的董事会任职。她此前曾在Zogenix, Inc.(ZGNX)的全资子公司Zogenix International Ltd.的董事会任职。Farfel博士拥有芝加哥大学神经精神药理学博士学位,在那里她获得了金斯堡论文优秀奖,并且是医学和生物科学校友委员会的董事。她还拥有弗吉尼亚大学生物化学学士学位。
Gail Farfel,has served as a member of Avrobio, Inc. board of directors since October 2020. Dr. Farfel is the chief executive officer of ProMIS Neurosciences, Inc., a biopharmaceutical company, and has served in this role since September 2022. From June 2015 to September 2022, Dr. Farfel was executive vice president and chief development officer of Zogenix Inc., a biopharmaceutical company. Previously, Dr. Farfel was chief clinical and regulatory officer of Marinus Pharmaceuticals (Nasdaq: MRNS), establishing and overseeing clinical, medical and regulatory strategies for adult and pediatric seizure disorders, including a pediatric epileptic orphan disease. She also previously served as vice president, therapeutic area head for neuroscience clinical development and medical affairs at Novartis Pharmaceuticals Corporation, where she oversaw a portfolio of products for multiple sclerosis, Alzheimer's disease and Parkinson's disease. Dr. Farfel serves on the board of directors of Durect Corporation (Nasdaq: DRRX). She previously served on the board of directors of Zogenix International Ltd., a wholly owned subsidiary of Zogenix, Inc. (Nasdaq: ZGNX). Dr Farfel holds a Ph.D. in neuropsychopharmacology from the University of Chicago, where she received the Ginsburg Prize for Dissertation Excellence and is a director on the Medical and Biological Sciences Alumni Board. She also holds a B.S in biochemistry from the University of Virginia.
Philip J. Vickers

Philip J. Vickers,自2019年1月起担任Avrobio,Inc.董事会成员。维克斯博士在2021年1月至2022年11月期间担任生物技术公司Faze Medicines的首席执行官。从2017年11月到2020年12月,维克斯博士担任生物技术公司Northern Biologics Inc.的总裁兼首席执行官和董事会成员。从2013年6月到2017年6月,Vickers博士担任Shire plc的全球研发主管和执行委员会成员,Shire plc是一家生物技术公司,专注于开发治疗罕见和特殊情况的疗法。2010年10月至2013年9月,Vickers博士在Shire担任高级副总裁、人类基因疗法研发主管。在加入Shire之前,Vickers博士曾在默克制药公司、辉瑞公司、Boehringer-Ingelheim International GmbH和Resolvyx Pharmaceuticals,Inc.担任越来越重要的研发职务。Vickers博士在生物技术公司Revance Therapeutics, Inc.或Revance(纳斯达克:RVNC)的董事会任职,并将继续在Revance董事会任职至Revance 2023年度会议。Vickers博士还担任PTEN研究基金会的科学顾问。Vickers博士在多伦多大学获得生物化学博士学位,随后在马里兰州贝塞斯达的国家癌症研究所进行了乳腺癌多药耐药机制的博士后研究。


Philip J. Vickers,has served as a member of Avrobio, Inc. board of directors since January 2019. Dr. Vickers was the chief executive officer of Faze Medicines, a biotechnology company from January 2021 to November 2022. From November 2017 until December 2020, Dr. Vickers served as the president and chief executive officer and a member of the board of directors of Northern Biologics Inc., a biotechnology company. From June 2013 until June 2017, Dr. Vickers served as global head of research and development and a member of the executive committee of Shire plc, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. From October 2010 to September 2013, Dr. Vickers served as the senior vice president, head of research and development, human genetic therapies at Shire. Prior to Shire, Dr. Vickers held positions of increasing responsibility in research and development at Merck & Co., Inc., Pfizer Inc., Boehringer-Ingelheim International GmbH and Resolvyx Pharmaceuticals, Inc. Dr. Vickers serves on the board of directors of Revance Therapeutics, Inc., or Revance (Nasdaq: RVNC), a biotechnology company, and will continue to serve on the Revance board until the Revance 2023 annual meeting. Dr. Vickers also serves as a scientific advisor to the PTEN Research Foundation. Dr. Vickers obtained his Ph.D. in biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
Philip J. Vickers,自2019年1月起担任Avrobio,Inc.董事会成员。维克斯博士在2021年1月至2022年11月期间担任生物技术公司Faze Medicines的首席执行官。从2017年11月到2020年12月,维克斯博士担任生物技术公司Northern Biologics Inc.的总裁兼首席执行官和董事会成员。从2013年6月到2017年6月,Vickers博士担任Shire plc的全球研发主管和执行委员会成员,Shire plc是一家生物技术公司,专注于开发治疗罕见和特殊情况的疗法。2010年10月至2013年9月,Vickers博士在Shire担任高级副总裁、人类基因疗法研发主管。在加入Shire之前,Vickers博士曾在默克制药公司、辉瑞公司、Boehringer-Ingelheim International GmbH和Resolvyx Pharmaceuticals,Inc.担任越来越重要的研发职务。Vickers博士在生物技术公司Revance Therapeutics, Inc.或Revance(纳斯达克:RVNC)的董事会任职,并将继续在Revance董事会任职至Revance 2023年度会议。Vickers博士还担任PTEN研究基金会的科学顾问。Vickers博士在多伦多大学获得生物化学博士学位,随后在马里兰州贝塞斯达的国家癌症研究所进行了乳腺癌多药耐药机制的博士后研究。
Philip J. Vickers,has served as a member of Avrobio, Inc. board of directors since January 2019. Dr. Vickers was the chief executive officer of Faze Medicines, a biotechnology company from January 2021 to November 2022. From November 2017 until December 2020, Dr. Vickers served as the president and chief executive officer and a member of the board of directors of Northern Biologics Inc., a biotechnology company. From June 2013 until June 2017, Dr. Vickers served as global head of research and development and a member of the executive committee of Shire plc, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. From October 2010 to September 2013, Dr. Vickers served as the senior vice president, head of research and development, human genetic therapies at Shire. Prior to Shire, Dr. Vickers held positions of increasing responsibility in research and development at Merck & Co., Inc., Pfizer Inc., Boehringer-Ingelheim International GmbH and Resolvyx Pharmaceuticals, Inc. Dr. Vickers serves on the board of directors of Revance Therapeutics, Inc., or Revance (Nasdaq: RVNC), a biotechnology company, and will continue to serve on the Revance board until the Revance 2023 annual meeting. Dr. Vickers also serves as a scientific advisor to the PTEN Research Foundation. Dr. Vickers obtained his Ph.D. in biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
Bruce Booth

Bruce Booth, 博士学位。自2006年8月起担任公司董事。2005年加入 Atlas Venture,现任生命科学集团合伙人。之前从2004年到2005年他担任Caxton Health Holdings L.L.C.(一家以健康理疗为中小的投资公司)主要负责人,主要负责公司的风险资本活动。加入 Caxton之前,从1999年到2004年他是 McKinsey & Company(一家全球战略管理咨询公司)联营负责人,为生物制药部门客户提供研发生产力,企业战略和业务发展问题建议。现任Miragen Therapeutics, Bicycle Therapeutics, Nimbus Discovery, Rodin Therapeutics和多个种子阶段的生物技术公司董事。此外,他还担任UCB Pharma新药物科学顾问董事会成员;他还参加了多个制药公司和学术研究中心的顾问董事会。他也是the New York Academy of Medicine信托人 。作为British Marshall Scholar学者,他持有牛津大学(Oxford University)Nuffield医学系分子免疫学博士学位;并获得宾夕法尼亚州立大学(the Pennsylvania State University)生物化学荣誉学士学位。


Bruce Booth,has served as the chairperson of Avrobio, Inc. board of directors since February 2016. Dr. Booth joined Atlas Venture in 2005, and currently serves as general partner. Previously, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm's venture capital activities. Prior to Caxton, from 1999 to 2004, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector. Dr. Booth is chairman and co-founder of Kymera Therapeutics, Inc. (Nasdaq: KYMR), chairman of Vigil Neuroscience (Nasdaq: VIGL), and serves on the board of Magenta Therapeutics, Inc. (Nasdaq: MGTA), all of which are biotechnology companies. He also serves on the board of several privately held companies. From February 2018 until July 2020, Dr. Booth served as chairperson of the board of directors of Unum Therapeutics Inc. (Nasdaq: UMRX), now called Cogent Biosciences (Nasdaq: COGT); from February 2017 until December 2018, Dr. Booth served as independent chairperson of the board of directors of miRagen Therapeutics, Inc. (Nasdaq: MGEN), now called Viridian Therapeutics, Inc (Nasdaq: VRDN); and from August 2006 until June 2018, Dr. Booth served on the board of directors of Zafgen, Inc. (Nasdaq: ZFGN), now called Larimar Therapeutics, Inc. (Nasdaq: LRMR). As a British Marshall Scholar, Dr. Booth holds a D.Phil. in molecular immunology from Oxford University's Nuffield Department of Medicine and a B.S. in biochemistry, summa cum laude, from Pennsylvania State University.
Bruce Booth, 博士学位。自2006年8月起担任公司董事。2005年加入 Atlas Venture,现任生命科学集团合伙人。之前从2004年到2005年他担任Caxton Health Holdings L.L.C.(一家以健康理疗为中小的投资公司)主要负责人,主要负责公司的风险资本活动。加入 Caxton之前,从1999年到2004年他是 McKinsey & Company(一家全球战略管理咨询公司)联营负责人,为生物制药部门客户提供研发生产力,企业战略和业务发展问题建议。现任Miragen Therapeutics, Bicycle Therapeutics, Nimbus Discovery, Rodin Therapeutics和多个种子阶段的生物技术公司董事。此外,他还担任UCB Pharma新药物科学顾问董事会成员;他还参加了多个制药公司和学术研究中心的顾问董事会。他也是the New York Academy of Medicine信托人 。作为British Marshall Scholar学者,他持有牛津大学(Oxford University)Nuffield医学系分子免疫学博士学位;并获得宾夕法尼亚州立大学(the Pennsylvania State University)生物化学荣誉学士学位。
Bruce Booth,has served as the chairperson of Avrobio, Inc. board of directors since February 2016. Dr. Booth joined Atlas Venture in 2005, and currently serves as general partner. Previously, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm's venture capital activities. Prior to Caxton, from 1999 to 2004, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector. Dr. Booth is chairman and co-founder of Kymera Therapeutics, Inc. (Nasdaq: KYMR), chairman of Vigil Neuroscience (Nasdaq: VIGL), and serves on the board of Magenta Therapeutics, Inc. (Nasdaq: MGTA), all of which are biotechnology companies. He also serves on the board of several privately held companies. From February 2018 until July 2020, Dr. Booth served as chairperson of the board of directors of Unum Therapeutics Inc. (Nasdaq: UMRX), now called Cogent Biosciences (Nasdaq: COGT); from February 2017 until December 2018, Dr. Booth served as independent chairperson of the board of directors of miRagen Therapeutics, Inc. (Nasdaq: MGEN), now called Viridian Therapeutics, Inc (Nasdaq: VRDN); and from August 2006 until June 2018, Dr. Booth served on the board of directors of Zafgen, Inc. (Nasdaq: ZFGN), now called Larimar Therapeutics, Inc. (Nasdaq: LRMR). As a British Marshall Scholar, Dr. Booth holds a D.Phil. in molecular immunology from Oxford University's Nuffield Department of Medicine and a B.S. in biochemistry, summa cum laude, from Pennsylvania State University.

高管简历

中英对照 |  中文 |  英文
Erik Ostrowski

Erik Ostrowski从2014年6月开始担任Summit Therapeutics Inc.首席财务官。加入Summit Therapeutics Inc.前,从2010年到2014年,Ostrowski先生担任生物技术公司Organogenesis Inc.的财务部副总裁。在这之前,Ostrowski先生在投资银行业任职,最后担任Leerink Partners LLC.的董事。Ostrowski先生在永道国际会计公司(Coopers & Lybrand担任会计师而开启其职业生涯。Ostrowski先生在美国巴布森学院(Babson College)获得会计学和经济学理学学士学位,在芝加哥大学(University of Chicago)布斯商学院获得工商管理硕士学位。


Erik Ostrowski,has been Avrobio, Inc. Chief Financial Officer and Treasurer since January 2019 and has also served as Avrobio, Inc. President and Interim Chief Executive Officer since May 1, 2023. From June 2014 to December 2018, Mr. Ostrowski served as the chief financial officer of Summit Therapeutics plc., a biotechnology company. Prior to that, he served as vice president of finance at Organogenesis Inc., a biotechnology company, from July 2010 to June 2014, and previously worked in investment banking, most recently as a director with Leerink Partners LLC. Mr. Ostrowski began his career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers). Mr. Ostrowski has served on the board of directors of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) since April 2022. He received a B.S. in accounting and economics from Babson College and a M.B.A. from the University of Chicago Booth School of Business.
Erik Ostrowski从2014年6月开始担任Summit Therapeutics Inc.首席财务官。加入Summit Therapeutics Inc.前,从2010年到2014年,Ostrowski先生担任生物技术公司Organogenesis Inc.的财务部副总裁。在这之前,Ostrowski先生在投资银行业任职,最后担任Leerink Partners LLC.的董事。Ostrowski先生在永道国际会计公司(Coopers & Lybrand担任会计师而开启其职业生涯。Ostrowski先生在美国巴布森学院(Babson College)获得会计学和经济学理学学士学位,在芝加哥大学(University of Chicago)布斯商学院获得工商管理硕士学位。
Erik Ostrowski,has been Avrobio, Inc. Chief Financial Officer and Treasurer since January 2019 and has also served as Avrobio, Inc. President and Interim Chief Executive Officer since May 1, 2023. From June 2014 to December 2018, Mr. Ostrowski served as the chief financial officer of Summit Therapeutics plc., a biotechnology company. Prior to that, he served as vice president of finance at Organogenesis Inc., a biotechnology company, from July 2010 to June 2014, and previously worked in investment banking, most recently as a director with Leerink Partners LLC. Mr. Ostrowski began his career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers). Mr. Ostrowski has served on the board of directors of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) since April 2022. He received a B.S. in accounting and economics from Babson College and a M.B.A. from the University of Chicago Booth School of Business.
Erik Ostrowski

Erik Ostrowski,自2019年1月起担任AVROBIO, Inc.,自2019年1月起担任AVROBIO, Inc.首席财务官和财务主管,并自2023年5月1日起担任TERM3总裁兼临时首席执行官。2014年6月至2018年12月,Ostrowski先生担任生物技术公司Summit Therapeutics PLC.的首席财务官。在此之前,他于2010年7月至2014年6月在生物技术公司Organogenesis公司担任财务副总裁,此前曾从事投资银行工作,最近在Leerink Partners LLC担任董事。Ostrowski先生的职业生涯始于Coopers & Lybrand(现为普华永道会计师事务所)的会计师。Ostrowski先生自2022年4月起担任Faron Pharmaceuticals OY(AIM:FARN,First North:FARON)的董事会成员。他在巴布森学院获得会计和经济学学士学位,在芝加哥大学布斯商学院获得工商管理硕士学位。


Erik Ostrowski,has been Avrobio, Inc. Chief Financial Officer and Treasurer since January 2019 and has also served as Avrobio, Inc. President and Interim Chief Executive Officer since May 1, 2023. From June 2014 to December 2018, Mr. Ostrowski served as the chief financial officer of Summit Therapeutics plc., a biotechnology company. Prior to that, he served as vice president of finance at Organogenesis Inc., a biotechnology company, from July 2010 to June 2014, and previously worked in investment banking, most recently as a director with Leerink Partners LLC. Mr. Ostrowski began his career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers). Mr. Ostrowski has served on the board of directors of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) since April 2022. He received a B.S. in accounting and economics from Babson College and a M.B.A. from the University of Chicago Booth School of Business.
Erik Ostrowski,自2019年1月起担任AVROBIO, Inc.,自2019年1月起担任AVROBIO, Inc.首席财务官和财务主管,并自2023年5月1日起担任TERM3总裁兼临时首席执行官。2014年6月至2018年12月,Ostrowski先生担任生物技术公司Summit Therapeutics PLC.的首席财务官。在此之前,他于2010年7月至2014年6月在生物技术公司Organogenesis公司担任财务副总裁,此前曾从事投资银行工作,最近在Leerink Partners LLC担任董事。Ostrowski先生的职业生涯始于Coopers & Lybrand(现为普华永道会计师事务所)的会计师。Ostrowski先生自2022年4月起担任Faron Pharmaceuticals OY(AIM:FARN,First North:FARON)的董事会成员。他在巴布森学院获得会计和经济学学士学位,在芝加哥大学布斯商学院获得工商管理硕士学位。
Erik Ostrowski,has been Avrobio, Inc. Chief Financial Officer and Treasurer since January 2019 and has also served as Avrobio, Inc. President and Interim Chief Executive Officer since May 1, 2023. From June 2014 to December 2018, Mr. Ostrowski served as the chief financial officer of Summit Therapeutics plc., a biotechnology company. Prior to that, he served as vice president of finance at Organogenesis Inc., a biotechnology company, from July 2010 to June 2014, and previously worked in investment banking, most recently as a director with Leerink Partners LLC. Mr. Ostrowski began his career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers). Mr. Ostrowski has served on the board of directors of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) since April 2022. He received a B.S. in accounting and economics from Babson College and a M.B.A. from the University of Chicago Booth School of Business.
Steven Avruch

Steven Avruch,自2020年3月起担任AVROBIO, Inc.首席法务官兼秘书,此前曾于2019年1月至2020年3月担任AVROBIO, Inc.副总裁、总法律顾问兼秘书。在加入AVROBIO, Inc.公司之前,2018年5月至2018年12月,Avruch先生是生物技术和其他公司的独立法律顾问。在此之前,Avruch先生曾任职于生物技术公司Biogen Inc.,于2015年1月至2017年12月担任首席公司法律顾问和助理秘书,并于2013年3月至2014年12月担任协理总法律顾问。Avruch先生毕业于达特茅斯学院,获得俄罗斯研究A.B.学位,后来在波士顿学院法学院获得法学博士学位。


Steven Avruch,has been Avrobio, Inc. Chief Legal Officer and Secretary since March 2020 and previously served as Avrobio, Inc. Vice President, General Counsel and Secretary from January 2019 to March 2020. Prior to joining Avrobio, Inc. Company, from May 2018 to December 2018, Mr. Avruch was an independent legal consultant to biotechnology and other companies. Prior to that, Mr. Avruch served at Biogen Inc., a biotechnology company, as chief corporation counsel and assistant secretary from January 2015 to December 2017, and as associate general counsel from March 2013 to December 2014. Mr. Avruch graduated with an A.B. in Russian Studies from Dartmouth College, and later earned his J.D. from Boston College Law School.
Steven Avruch,自2020年3月起担任AVROBIO, Inc.首席法务官兼秘书,此前曾于2019年1月至2020年3月担任AVROBIO, Inc.副总裁、总法律顾问兼秘书。在加入AVROBIO, Inc.公司之前,2018年5月至2018年12月,Avruch先生是生物技术和其他公司的独立法律顾问。在此之前,Avruch先生曾任职于生物技术公司Biogen Inc.,于2015年1月至2017年12月担任首席公司法律顾问和助理秘书,并于2013年3月至2014年12月担任协理总法律顾问。Avruch先生毕业于达特茅斯学院,获得俄罗斯研究A.B.学位,后来在波士顿学院法学院获得法学博士学位。
Steven Avruch,has been Avrobio, Inc. Chief Legal Officer and Secretary since March 2020 and previously served as Avrobio, Inc. Vice President, General Counsel and Secretary from January 2019 to March 2020. Prior to joining Avrobio, Inc. Company, from May 2018 to December 2018, Mr. Avruch was an independent legal consultant to biotechnology and other companies. Prior to that, Mr. Avruch served at Biogen Inc., a biotechnology company, as chief corporation counsel and assistant secretary from January 2015 to December 2017, and as associate general counsel from March 2013 to December 2014. Mr. Avruch graduated with an A.B. in Russian Studies from Dartmouth College, and later earned his J.D. from Boston College Law School.
Azadeh Golipour

Azadeh Golipour,自2022年1月起担任AVROBIO, Inc.首席技术官。在此之前,她于2021年10月至2022年1月担任投资组合规划和项目管理高级副总裁。从2016年7月到2021年10月,Golipour博士在AVROBIO, Inc.公司担任越来越重要的职务,包括:CMC Strategy & Manufacturing高级副总裁;制造运营副总裁;制造运营高级总监;制造运营总监。Golipour博士在多伦多大学(加拿大)获得分子遗传学博士学位,并发表了多篇文章,包括在《Cell,Stem Cell》杂志上发表的两篇第一作者文章和在《自然》杂志上发表的一篇文章。Golipour博士关于重编程干细胞的文章被引用了1000多次。


Azadeh Golipour,has been Avrobio, Inc. Chief Technology Officer since January 2022. Prior to that she was SVP, Portfolio Planning and Program Management from October 2021 to January 2022. From July 2016 through October 2021 Dr. Golipour held positions of increasing responsibility at Avrobio, Inc. Company, including: SVP, CMC Strategy & Manufacturing; VP, Manufacturing Operations; Senior Director, Manufacturing Operations; and Director, Manufacturing Operations. Dr. Golipour received a Ph.D. in molecular genetics from University of Toronto (Canada) and has published multiple articles, including two first-author articles in the journal Cell, Stem Cell and one article in the journal Nature. Dr. Golipour's articles on reprogramming stem cells have been cited more than 1,000 times.
Azadeh Golipour,自2022年1月起担任AVROBIO, Inc.首席技术官。在此之前,她于2021年10月至2022年1月担任投资组合规划和项目管理高级副总裁。从2016年7月到2021年10月,Golipour博士在AVROBIO, Inc.公司担任越来越重要的职务,包括:CMC Strategy & Manufacturing高级副总裁;制造运营副总裁;制造运营高级总监;制造运营总监。Golipour博士在多伦多大学(加拿大)获得分子遗传学博士学位,并发表了多篇文章,包括在《Cell,Stem Cell》杂志上发表的两篇第一作者文章和在《自然》杂志上发表的一篇文章。Golipour博士关于重编程干细胞的文章被引用了1000多次。
Azadeh Golipour,has been Avrobio, Inc. Chief Technology Officer since January 2022. Prior to that she was SVP, Portfolio Planning and Program Management from October 2021 to January 2022. From July 2016 through October 2021 Dr. Golipour held positions of increasing responsibility at Avrobio, Inc. Company, including: SVP, CMC Strategy & Manufacturing; VP, Manufacturing Operations; Senior Director, Manufacturing Operations; and Director, Manufacturing Operations. Dr. Golipour received a Ph.D. in molecular genetics from University of Toronto (Canada) and has published multiple articles, including two first-author articles in the journal Cell, Stem Cell and one article in the journal Nature. Dr. Golipour's articles on reprogramming stem cells have been cited more than 1,000 times.
Deanna Petersen

Deanna Petersen,自2016年1月起担任AVROBIO, Inc.首席商务官。在加入AVROBIO, Inc.公司之前,2009年6月至2015年6月,Petersen女士在Shire PLC担任开发性罕见病业务副总裁。在此之前,Petersen女士曾于2002年4月至2009年3月在Agenus Inc.担任业务发展副总裁,并在Coley Pharmaceutical Group担任业务发展副总裁。Petersen女士获得了爱荷华州立大学生物学学士学位和爱荷华大学工商管理硕士学位。


Deanna Petersen,has been Avrobio, Inc. Chief Business Officer since January 2016. Prior to joining Avrobio, Inc. Company, from June 2009 to June 2015, Ms. Petersen was vice president business of development rare diseases at Shire plc. Prior to that, Ms. Petersen served as vice president of business development at Agenus Inc. from April 2002 to March 2009 and vice president of business development at Coley Pharmaceutical Group. Ms. Petersen received a B.S. degree in biology from Iowa State University and a M.B.A. from the University of Iowa.
Deanna Petersen,自2016年1月起担任AVROBIO, Inc.首席商务官。在加入AVROBIO, Inc.公司之前,2009年6月至2015年6月,Petersen女士在Shire PLC担任开发性罕见病业务副总裁。在此之前,Petersen女士曾于2002年4月至2009年3月在Agenus Inc.担任业务发展副总裁,并在Coley Pharmaceutical Group担任业务发展副总裁。Petersen女士获得了爱荷华州立大学生物学学士学位和爱荷华大学工商管理硕士学位。
Deanna Petersen,has been Avrobio, Inc. Chief Business Officer since January 2016. Prior to joining Avrobio, Inc. Company, from June 2009 to June 2015, Ms. Petersen was vice president business of development rare diseases at Shire plc. Prior to that, Ms. Petersen served as vice president of business development at Agenus Inc. from April 2002 to March 2009 and vice president of business development at Coley Pharmaceutical Group. Ms. Petersen received a B.S. degree in biology from Iowa State University and a M.B.A. from the University of Iowa.
Essra Ridha

Essra Ridha,自2021年10月起担任AVROBIO, Inc.首席医疗官,2021年4月至2021年7月,担任AVROBIO, Inc.临床开发副总裁。在加入AVROBIO, Inc.公司之前,2019年6月至2021年2月,Ridha博士在生物技术公司Sangamo Therapeutics担任高级医疗总监,在此之前,2016年3月至2018年12月,她在制药公司葛兰素史克担任临床开发总监。从2014年6月到2016年3月,Ridha博士在Bristol Myers Squibb Pharmaceuticals担任医学专家,为心血管医学的后期临床开发、医学事务、真实世界证据和健康经济学以及结果研究提供建议。Ridha博士是伦敦皇家内科医学院的成员,也是药学医学院的院士。她是世界卫生组织专家咨询委员会的专家小组成员,该委员会负责制定人类基因组编辑治理和监督的全球标准。她获得了伦敦皇家自由大学医学院的医学学位,并以优异的成绩获得了伦敦大学学院的科学神经科学和基础医学科学学士学位。


Essra Ridha,has been Avrobio, Inc. Chief Medical Officer since October 2021, and from April 2021 to July 2021, she was Avrobio, Inc. Vice President, Clinical Development. Prior to joining Avrobio, Inc. Company, from June 2019 to February 2021, Dr. Ridha was Senior Medical Director at Sangamo Therapeutics, a biotechnology company, and before that, from March 2016 to December 2018, she served as Clinical Development Director at GlaxoSmithKline, a pharmaceutical company. From June 2014 to March 2016, Dr. Ridha worked as a medical expert at Bristol Myers Squibb Pharmaceuticals advising on late-stage clinical development, medical affairs, real-world evidence and health economics and outcomes research in cardiovascular medicine. Dr. Ridha is a member of the Royal College of Physicians of London, as well as a Fellow of the Faculty of Pharmaceutical Medicine. She was an expert panel member at the World Health Organization Expert Advisory Committee to develop Global Standards for the Governance and Oversight of Human Genome Editing. She earned her medical degrees from the Royal Free & University College London Medical School and earned her Bachelor of Science Neuroscience with Basic Medical Sciences, with honors, from University College London.
Essra Ridha,自2021年10月起担任AVROBIO, Inc.首席医疗官,2021年4月至2021年7月,担任AVROBIO, Inc.临床开发副总裁。在加入AVROBIO, Inc.公司之前,2019年6月至2021年2月,Ridha博士在生物技术公司Sangamo Therapeutics担任高级医疗总监,在此之前,2016年3月至2018年12月,她在制药公司葛兰素史克担任临床开发总监。从2014年6月到2016年3月,Ridha博士在Bristol Myers Squibb Pharmaceuticals担任医学专家,为心血管医学的后期临床开发、医学事务、真实世界证据和健康经济学以及结果研究提供建议。Ridha博士是伦敦皇家内科医学院的成员,也是药学医学院的院士。她是世界卫生组织专家咨询委员会的专家小组成员,该委员会负责制定人类基因组编辑治理和监督的全球标准。她获得了伦敦皇家自由大学医学院的医学学位,并以优异的成绩获得了伦敦大学学院的科学神经科学和基础医学科学学士学位。
Essra Ridha,has been Avrobio, Inc. Chief Medical Officer since October 2021, and from April 2021 to July 2021, she was Avrobio, Inc. Vice President, Clinical Development. Prior to joining Avrobio, Inc. Company, from June 2019 to February 2021, Dr. Ridha was Senior Medical Director at Sangamo Therapeutics, a biotechnology company, and before that, from March 2016 to December 2018, she served as Clinical Development Director at GlaxoSmithKline, a pharmaceutical company. From June 2014 to March 2016, Dr. Ridha worked as a medical expert at Bristol Myers Squibb Pharmaceuticals advising on late-stage clinical development, medical affairs, real-world evidence and health economics and outcomes research in cardiovascular medicine. Dr. Ridha is a member of the Royal College of Physicians of London, as well as a Fellow of the Faculty of Pharmaceutical Medicine. She was an expert panel member at the World Health Organization Expert Advisory Committee to develop Global Standards for the Governance and Oversight of Human Genome Editing. She earned her medical degrees from the Royal Free & University College London Medical School and earned her Bachelor of Science Neuroscience with Basic Medical Sciences, with honors, from University College London.